Xerophthalmos (Severe) - Causes, Treatment & When to See a Doctor

```html

What is Xerophthalmos (Severe)?

Xerophthalmos refers to an abnormal dryness of the ocular surface, most often described as a “dry eye” condition. When the term “severe” is added, it means the dryness is profound enough to cause significant discomfort, visual disturbance, and damage to the cornea or conjunctiva. In severe xerophthalmos, the tear film is insufficient in volume **and** quality, leading to a loss of the protective mucus‑lipid‑aqueous layer that normally keeps the eye moist, lubricated, and free of infection.

Patients with severe xerophthalmos may experience a gritty or burning sensation, persistent redness, and, in advanced cases, corneal ulceration or scarring that can threaten vision. The condition can be chronic (lasting months to years) or acute when triggered by a sudden systemic event such as medication toxicity or an autoimmune flare.

According to the National Institute of Eye Health, severe dry eye disease is one of the leading causes of ocular morbidity worldwide and is often under‑diagnosed because patients may adapt to mild discomfort and delay seeking care.

Common Causes

Severe xerophthalmos is usually multifactorial. Below are the most frequent underlying conditions (listed alphabetically):

• Autoimmune diseases – Sjögren’s syndrome, rheumatoid arthritis, systemic lupus erythematosus, and graft‑versus‑host disease produce inflammatory damage to lacrimal glands.
• Medications – Antihistamines, tricyclic antidepressants, isotretinoin, diuretics, and certain chemotherapy agents (e.g., taxanes) reduce tear production.
• Meibomian gland dysfunction (MGD) – Obstruction or atrophy of the oil‑secreting glands leads to an unstable lipid layer.
• Radiation therapy – Head and neck or orbital radiation damages lacrimal gland tissue.
• Severe eyelid disorders – Blepharitis, entropion, ectropion, or lagophthalmos (incomplete eyelid closure) increase exposure.
• Systemic dehydration – Chronic fluid loss from poorly controlled diabetes, severe vomiting, or diuretic overuse.
• Neurotrophic keratopathy – Damage to corneal sensory nerves (e.g., after herpes simplex keratitis or trigeminal nerve injury) impairs reflex tearing.
• Age‑related decline – Tear production naturally falls after age 50, especially in post‑menopausal women.
• Vitamin A deficiency – Rare in developed nations but severe deficiency can cause keratinization of the conjunctiva and xerophthalmos.
• Contact lens wear – Long‑term wear, especially of silicone‑hydrogel lenses, can disrupt tear dynamics.

Associated Symptoms

Patients with severe xerophthalmos often report a constellation of ocular and systemic signs. Common co‑occurring symptoms include:

• Burning, stinging, or gritty sensation (“sand in the eye”).
• Excessive tearing (reflex tearing) despite dryness.
• Blurred vision that improves with blinking.
• Redness of the sclera or conjunctiva.
• Sensitivity to light (photophobia).
• Feeling of a foreign body or “contact lens sensation.”
• Stringy mucus discharge.
• Eye fatigue, especially after reading or screen use.
• Recurrent corneal abrasions or ulcerations.
• In systemic autoimmune disease: dry mouth (xerostomia), joint pain, or skin rashes.

When to See a Doctor

Because severe xerophthalmos can progress to vision‑threatening complications, timely evaluation is essential. Seek professional care if you experience any of the following:

• Persistent burning or pain that does not improve with over‑the‑counter lubricants.
• Sudden onset of visual disturbance (blurred or double vision).
• Redness that spreads beyond the eyelids or is accompanied by a yellow/green discharge.
• Frequent episodes of eye rubbing or a feeling that the eye is “stuck open.”
• Signs of corneal ulceration—small white spots, a hazy area, or a feeling of a “scratch” that does not heal.
• Systemic symptoms suggestive of an autoimmune disease (dry mouth, joint swelling, rash).

Early referral to an ophthalmologist or optometrist can prevent permanent corneal scarring.

Diagnosis

Diagnosis of severe xerophthalmos involves both a detailed history and a series of objective tests performed by an eye‑care professional.

1. Clinical History & Examination

• Medication review (especially anticholinergics, isotretinoin, antihistamines).
• Screening for systemic diseases (rheumatologic, endocrine, nutritional).
• Assessment of environmental factors (low humidity, screen time, air conditioning).
• External eye exam with slit‑lamp microscopy to look for punctate epithelial erosions, conjunctival staining, or meibomian gland plugging.

2. Objective Tests

• Schirmer test – Strips of filter paper placed under the lower eyelid for 5 minutes; <5 mm wetting suggests severe aqueous deficiency.
• Tear Break‑up Time (TBUT) – Fluorescein dye is applied; a break‑up time <5 seconds indicates an unstable tear film.
• Ocular Surface Staining – Graded with the Oxford or NEI scale to document epithelial damage.
• Meibomian Gland Imaging – Infrared or meibography to assess gland dropout.
• Inflammatory Markers – Tear cytokine analysis (e.g., matrix metalloproteinase‑9) can help gauge ocular surface inflammation.
• Serologic testing – ANA, RF, anti‑SSA/SSB antibodies when autoimmune etiology is suspected.

Treatment Options

Management is individualized and usually involves a stepwise approach: lubricate, protect, reduce inflammation, and treat underlying disease.

1. Lubrication & Tear Film Restoration

• Artificial tears – Preservative‑free drops used 4–6 times daily; hyaluronic acid formulations have longer residence time.
• Gel and ointments – Apply at night to maintain moisture while sleeping.
• Lubricating eye masks – Provide continuous moisture for patients with severe exposure.
• Autologous serum eye drops – Contain natural growth factors; used for refractory cases (prescribed by a specialist).

2. Reducing Evaporation

• Punctal plugs – Small silicone or collagen devices inserted into tear ducts to retain tears.
• Lipid‑based eye drops – Contain castor oil or mineral oil to supplement the tear film’s oily layer.
• Warm compresses & lid massage – Help melt meibum and unblock meibomian glands.
• Intense Pulsed Light (IPL) therapy – Reduces abnormal vessels and improves gland function in MGD.

3. Controlling Inflammation

• Topical corticosteroids – Short‑course (e.g., prednisolone acetate 1 %) for acute inflammation; monitor intra‑ocular pressure.
• Cyclo‑oxygenase‑2 (COX‑2) inhibitors – Topical (e.g., nepafenac) for milder inflammation.
• Cyclosporine A 0.05 % (Restasis) or Lifitegrast 5 % (Xiidra) – Immunomodulators that increase tear production and reduce ocular surface inflammation; may take 4–12 weeks to show effect.
• Systemic immunosuppressants – Hydroxychloroquine, azathioprine, or biologics (e.g., rituximab) for underlying autoimmune disease, prescribed by a rheumatologist.

4. Addressing Underlying Causes

• Discontinue or substitute offending medications after consulting the prescribing physician.
• Treat systemic disorders (e.g., start disease‑modifying antirheumatic drugs for Sjögren’s syndrome).
• Correct vitamin A deficiency with oral supplementation (typically 10,000 IU/day for 3–6 months).
• Manage eyelid malpositions surgically (e.g., tarsorrhaphy, ptosis repair).

5. Surgical & Advanced Options

• Lacrimal gland transplantation – Rare, reserved for extreme aqueous deficiency.
• Amniotic membrane transplantation – Provides a biologic bandage for persistent epithelial defects.
• Corneal limbal stem‑cell grafts – For cases where surface damage has led to stem‑cell deficiency.

Prevention Tips

While some risk factors (age, genetics) cannot be changed, many lifestyle and environmental modifications can reduce the likelihood of severe xerophthalmos or prevent its progression:

• Maintain adequate hydration – aim for at least 8 cups of water per day.
• Use a humidifier in dry indoor environments, especially during winter.
• Take regular breaks during screen use (20‑20‑20 rule: every 20 min look at something 20 ft away for 20 seconds).
• Wear protective sunglasses outdoors to reduce wind‑induced evaporation.
• Limit exposure to smoke, fumes, and strong air‑conditioning drafts.
• Follow a balanced diet rich in omega‑3 fatty acids (e.g., fatty fish, flaxseed) which support meibomian gland health.
• If you wear contact lenses, adhere to replacement schedules and give eyes a “lens‑free” day each week.
• Review medications with your physician; ask about alternatives if you take multiple anticholinergic drugs.
• Schedule routine eye exams (at least once a year) if you have known risk factors such as autoimmune disease.

Emergency Warning Signs

If any of the following occur, seek immediate ophthalmic or emergency care:

• Sudden loss of vision or rapid worsening of visual acuity.
• Severe eye pain unrelieved by lubricants.
• Marked redness with a hazy or white spot on the cornea (possible ulcer).
• Persistent photophobia accompanied by tearing or discharge.
• Signs of infection: swelling, pus, fever, or a foul odor.
• Eye trauma or chemical exposure in a patient already diagnosed with severe xerophthalmos.

Timely treatment can prevent permanent corneal scarring and preserve vision.

---

References:

1. Mayo Clinic. “Dry eye syndrome.” https://www.mayoclinic.org. Accessed June 2024.
2. National Eye Institute. “Dry Eye.” https://www.nei.nih.gov. 2023.
3. American Academy of Ophthalmology. “Management of Dry Eye Disease.” *Ophthalmology* 2022;129(3):e45‑e61.
4. World Health Organization. “Global Prevalence of Dry Eye Disease.” WHO Technical Report Series, 2021.
5. Cleveland Clinic. “Sjogren’s Syndrome.” https://my.clevelandclinic.org. 2024.
6. U.S. Centers for Disease Control and Prevention. “Vitamin A deficiency.” https://www.cdc.gov. 2022.

```